A new computer tool developed by scientists at the University of Oxford could help solve one of the biggest questions people ask before starting cholesterol-lowering medicine: “What are my real chances of getting serious muscle side effects?”
Instead of giving the same answer to everyone, the tool provides a personal estimate based on each person’s health.
Heart disease remains one of the leading causes of death worldwide. One of the main reasons is that cholesterol slowly builds up inside arteries over many years.
Statins reduce this harmful cholesterol and have been shown in many clinical trials to lower the risk of heart attacks and strokes. Even so, many people refuse treatment because they have heard stories about muscle problems.
Researchers from the Nuffield Department of Primary Care Health Sciences wanted to replace uncertainty with better evidence.
Their research was published in The Lancet Digital Health. They designed a calculator that estimates the risk of developing serious muscle disorders over the next one, five and ten years.
To create the model, the team analysed anonymous medical information from more than 5.6 million people in England. They first built the model using over 1.7 million patient records and then checked its performance in another 3.9 million records. This careful testing showed the calculator could accurately identify people with very low or higher risk.
The calculator considers 22 factors that doctors routinely record during normal healthcare visits. These include age, sex, ethnicity, body mass index, smoking, medical conditions, vitamin D deficiency, previous muscle disease, medicines and statin use. It combines all of this information to estimate an individual’s risk.
One of the most important findings was that serious muscle disorders were predicted to be very uncommon. More than 98% of people who were suitable for statin treatment had a low predicted risk during the next ten years. At the same time, researchers discovered a major treatment gap. More than six out of every ten people who were eligible for statins were not taking them, even though many had a substantial risk of future heart disease.
The researchers hope the calculator will help patients and doctors have more balanced conversations. Instead of focusing only on possible side effects, they can compare the small risk of serious muscle problems with the much greater benefit of preventing heart attacks and strokes.
Some patients who truly have a higher muscle risk may benefit from extra monitoring or alternative medicines, while most people can be reassured that severe side effects are unlikely.
The calculator also supports the wider goal of personalised healthcare. Modern medicine is moving away from treating everyone exactly the same. By estimating risk for each individual, doctors can tailor treatment more closely to a person’s own situation.
People should remember that no medicine is completely free from side effects, but avoiding an effective treatment because of an exaggerated fear may also carry serious risks. Anyone concerned about statins should discuss their options with their doctor rather than stopping medication without medical advice.
Study review and analysis: This research is impressive because of its exceptionally large database and strong validation process. The calculator has the potential to improve shared decision-making between patients and healthcare professionals.
However, it predicts risk rather than guaranteeing what will happen to one person, and future studies in other populations will strengthen confidence in its use.
Overall, the findings provide reassuring evidence that severe muscle complications from statins are rare for the overwhelming majority of eligible patients.
If you care about health, please read studies that vitamin D can help reduce inflammation, and vitamin K could lower your heart disease risk by a third.
For more health information, please see recent studies about new way to halt excessive inflammation, and results showing foods that could cause inflammation.
Source: University of Oxford.
